|
Source
|
Web search |
|
Organization
|
Sensei Biotherapeutics |
|
Website URL
|
senseibio.com |
|
Market status
|
Under Development |
|
Industry
|
Medical |
|
Value chain stage
|
Input |
|
Business models
|
B2C |
|
Product categories
|
Medical Treatment + Medicine |
|
Biotech components
|
Virus |
|
Organization type(s)
|
Private Company |
|
Funding types
|
Private Funding |
|
Known funding amount
|
$28,500,000 USD |
|
Notes
|
“Sensei Biotherapeutics has raised $28.5 million to advance a pipeline of personalized cancer drugs. The financing round comes weeks after Sensei shared clinical data on the effect of combining its lead asset SNS-301 with Merck’s checkpoint inhibitor Keytruda...SNS-301 is the most advanced example of Sensei’s immunophage approach. Sensei is engineering noninfectious lambda bacteriophage viruses to display target antigens. Upon entering an antigen-presenting cell, phage virions trigger a response that leads activated T cells to target the displayed tumor-associated antigen (TAA). Sensei plans to make personalized therapies out of off-the-shelf components, cutting the time it takes to deliver a treatment tailored to a patient’s tumor." |
Added 2 years ago
Last modified 2 years ago
